Exonate Sees Alternative mRNA Splicing Inhibitors As New Eye Disease Therapies
Executive Summary
Emerging Company Profile: Inhibitors of VEGF-A alternative mRNA splicing could deliver a step-change in the treatment of retinal eye diseases, hopes UK start-up Exonate.
You may also be interested in...
Roche Bi-Specific Antibody Has Eylea In Its Sights After Lucentis Win
Following the failure late last year of Regeneron's combination of Eylea with nesvacumab, a Phase II success for the Swiss major's RG7716 is a boost for the theory that a VEGF/Ang-2 combo therapy can transform the treatment of certain eye diseases.
Finance Watch: Mysterious Gossamer Raises $100m As VC Deals Surge Ahead of J.P. Morgan
Gossamer Bio, led by former Receptos CEO Faheem Hasnain and CMO Sheila Gujrathi, revealed $100m in seed and Series A funding during a week in which 17 companies revealed VC rounds totaling $891.2m, giving them good news to discuss during the J.P. Morgan Healthcare conference.
Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab
Novartis says nAMD eye treatment brolucizumab showed further advantages over Eylea in two Phase III studies, reinforcing plans to file in late 2018 for a commercial launch in 2019.